Efficacy and Clinical Safety Study of Rabeprazole Combined with Amoxicillin Dual Therapy for Type 2 Diabetes Mellitus Patients with Helicobacter pylori Infection

Objective: To explore the clinical efficacy, safety, and impact on inflammatory factor levels of rabeprazole combined with amoxicillin dual therapy in the treatment of patients with type 2 diabetes mellitus (T2DM) and Helicobacter pylori (Hp) infection, providing a reference for clinical treatment. Methods: A total of 526 patients with T2DM and Hp infection who were treated in our hospital from January 2022 to December 2024 were selected as the study subjects. Among them, 33 patients withdrew due to allergies or other reasons, and 493 patients completed the treatment. They were divided into a control group (n = 246) and an observation group (n = 247) using a random number table method. The control group received quadruple therapy, while the observation group received high-dose dual therapy. The general information, clinical efficacy, serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), hypersensitive C-reactive protein (hs-CRP), Hp eradication rate, recurrence rate, and incidence of adverse reactions were compared between the two groups. Results: After treatment, the indicators of both groups improved compared to before treatment. The observation group showed significant advantages in various indicator improvements: In terms of clinical efficacy, the observation group (95.144%) was significantly better than the control group (83.74%) (χ2 = 16.982, P = 0.000 < 0.001). Regarding inflammatory factor levels, IL-6, TNF-α, and hs-CRP levels decreased more significantly in the observation group compared to the control group (P = 0.000 < 0.001). In terms of Hp eradication rate and recurrence rate, the Hp eradication rate was higher in the observation group than in the control group (χ2 = 14.481, P = 0.000 < 0.001), and the recurrence rate was lower (χ2 = 32.740, P = 0.000 < 0.001). In terms of safety, the incidence of adverse reactions (4.04%) was lower in the observation group than in the control group (14.63%) (χ2 = 16.325, P = 0.000 < 0.01). Conclusion: Rabeprazole combined with amoxicillin dual therapy is effective in the treatment of patients with T2DM and Hp infection. It can effectively reduce inflammatory factor levels, improve the Hp eradication rate, reduce recurrence, and has high safety. It is worthy of clinical promotion and application.